E. Pecher

855 total citations
12 papers, 692 citations indexed

About

E. Pecher is a scholar working on Endocrinology, Diabetes and Metabolism, Gastroenterology and Molecular Biology. According to data from OpenAlex, E. Pecher has authored 12 papers receiving a total of 692 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Endocrinology, Diabetes and Metabolism, 5 papers in Gastroenterology and 3 papers in Molecular Biology. Recurrent topics in E. Pecher's work include Gastrointestinal motility and disorders (5 papers), Diabetes Treatment and Management (4 papers) and Metabolism, Diabetes, and Cancer (3 papers). E. Pecher is often cited by papers focused on Gastrointestinal motility and disorders (5 papers), Diabetes Treatment and Management (4 papers) and Metabolism, Diabetes, and Cancer (3 papers). E. Pecher collaborates with scholars based in Switzerland, Canada and United States. E. Pecher's co-authors include Brigitte Nault, I. Fumagalli, Fábio Pace, Karna Dev Bardhan, S. Müller‐Lissner, P. Rüegg, Floriane Cressier, Smiljana Ristič, Norman Muirhead and Florence Botteri and has published in prestigious journals such as Gastroenterology, Diabetes Care and European Heart Journal.

In The Last Decade

E. Pecher

12 papers receiving 656 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
E. Pecher Switzerland 10 467 288 163 136 91 12 692
Rachael S. Rigda Australia 14 182 0.4× 229 0.8× 153 0.9× 193 1.4× 50 0.5× 22 529
Katsunori Ito Japan 5 97 0.2× 91 0.3× 202 1.2× 86 0.6× 20 0.2× 14 458
Melanie K. Berry Australia 8 353 0.8× 161 0.6× 258 1.6× 159 1.2× 23 0.3× 10 564
M. L. Nusynowitz United States 5 204 0.4× 158 0.5× 91 0.6× 38 0.3× 232 2.5× 12 560
Imke Masuy Belgium 13 294 0.6× 172 0.6× 89 0.5× 20 0.1× 6 0.1× 22 423
F Ducrot France 5 332 0.7× 263 0.9× 85 0.5× 23 0.2× 15 0.2× 5 451
Anthony I. Stern Australia 13 138 0.3× 275 1.0× 62 0.4× 34 0.3× 16 0.2× 25 515
M. Bayless United States 8 56 0.1× 117 0.4× 101 0.6× 275 2.0× 86 0.9× 9 502
Aaron Tokayer United States 5 433 0.9× 206 0.7× 195 1.2× 21 0.2× 11 0.1× 15 559
Wynne Rees United Kingdom 6 226 0.5× 188 0.7× 92 0.6× 20 0.1× 21 0.2× 9 385

Countries citing papers authored by E. Pecher

Since Specialization
Citations

This map shows the geographic impact of E. Pecher's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by E. Pecher with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites E. Pecher more than expected).

Fields of papers citing papers by E. Pecher

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by E. Pecher. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by E. Pecher. The network helps show where E. Pecher may publish in the future.

Co-authorship network of co-authors of E. Pecher

This figure shows the co-authorship network connecting the top 25 collaborators of E. Pecher. A scholar is included among the top collaborators of E. Pecher based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with E. Pecher. E. Pecher is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

12 of 12 papers shown
1.
Fried, Michael, et al.. (2006). Efficacy of Tegaserod in Chronic Constipation in Men. The American Journal of Gastroenterology. 102(2). 362–370. 15 indexed citations
2.
Quigley, Eamonn M.M., et al.. (2006). Safety and Tolerability of Tegaserod in Patients With Chronic Constipation: Pooled Data From Two Phase III Studies. Clinical Gastroenterology and Hepatology. 4(5). 605–613. 25 indexed citations
3.
4.
5.
McMurray, John J.V., et al.. (2004). Cardiologists should care about glucose: most people with CV disease or risk factors have diabetes or significant glycaemic abnormalities. Results of screening over 39,000 subjects for NAVIGATOR. European Heart Journal. 25. 239–239. 6 indexed citations
6.
Reilly, Margaret C., et al.. (2004). TEGASEROD SIGNIFICANTLY REDUCES WORK PRODUCTIVITY LOSS AND DAILY ACTIVITY IMPAIRMENT IN PATIENTS WITH IBS WITH CONSTIPATION. The American Journal of Gastroenterology. 99. S241–S241. 3 indexed citations
7.
Saloranta, Carola, E. Pecher, Pedro de Pablos‐Velasco, et al.. (2002). Nateglinide Improves Early Insulin Secretion and Controls Postprandial Glucose Excursions in a Prediabetic Population. Diabetes Care. 25(12). 2141–2146. 28 indexed citations
8.
Tougas, Gervais, M.H. Otten, David L. Earnest, et al.. (2002). Long‐term safety of tegaserod in patients with constipation‐predominant irritable bowel syndrome. Alimentary Pharmacology & Therapeutics. 16(10). 1701–1708. 64 indexed citations
9.
Müller‐Lissner, S., I. Fumagalli, Karna Dev Bardhan, et al.. (2001). Tegaserod, a 5‐HT4 receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation. Alimentary Pharmacology & Therapeutics. 15(10). 1655–1666. 378 indexed citations
10.
Mueller‐Lissner, Stefan, I. Fumagalli, Fábio Heleno de Lima Pace, et al.. (2000). Tegaserod, a 5-HT4 receptor partial agonist, relieves key symptoms of irritable bowel syndrome (IBS). Gastroenterology. 118(4). A175–A175. 28 indexed citations
11.
Lewanczuk, R., et al.. (1999). THE EFFECT OF VALSARTAN AND CAPTOPRIL ON LIPID PARAMETERS IN PATIENTS WITH TYPE II DIABETES MELLITUS AND NEPHROPATHY. International Journal of Clinical Practice. 53(8). 584–592. 16 indexed citations
12.
Muirhead, Norman, Jeffrey L. Mahon, Richard Lewanczuk, et al.. (1999). The effects of valsartan and captopril on reducing microalbuminuria in patients with type 2 diabetes mellitus: a placebo-controlled trial. Current Therapeutic Research. 60(12). 650–660. 61 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Rachael S. Rigda Breakdown of academic impact, for papers by Katsunori Ito Breakdown of academic impact, for papers by Melanie K. Berry Breakdown of academic impact, for papers by M. L. Nusynowitz Breakdown of academic impact, for papers by Imke Masuy Breakdown of academic impact, for papers by F Ducrot Breakdown of academic impact, for papers by Anthony I. Stern Breakdown of academic impact, for papers by M. Bayless Breakdown of academic impact, for papers by Aaron Tokayer Breakdown of academic impact, for papers by Wynne Rees
Rankless by CCL
2026